ADC Therapeutics Reveals Promising ZYNLONTA® Data for Marginal Zone Lymphoma at ICML 2025 ADC Therapeutics presented significant findings on ZYNLONTA® for relapsed/refractory marginal zone lymphoma at the ICML, showcasing a high response rate and prolonged effectiveness.

ADC Therapeutics Reveals Promising ZYNLONTA® Data for Marginal Zone Lymphoma at ICML 2025 #Switzerland #ADC_Therapeutics #Lausanne #ZYNLONTA® #Marginal_Zone_Lymphoma